Markets
Immunovant Stock Soars 12% After Higher-Dose Arthritis Trial Success And A Narrower Loss
The lower dose failed to outperform placebo, while management plans FDA talks later this year on a path toward approval.
Immunovant (IMVT) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
The lower dose failed to outperform placebo, while management plans FDA talks later this year on a path toward approval.
Earnings
Higher-dose patients maintained arthritis responses, but FDA discussions will determine the next trial's design.
SEC Filings
The higher dose preserved responses in rheumatoid arthritis, while further development in Sjögren’s disease looks unlikely.